These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 16790324)

  • 21. Efficacy of memantine on behavioral and psychological symptoms related to dementia: a systematic meta-analysis.
    Maidment ID; Fox CG; Boustani M; Rodriguez J; Brown RC; Katona CL
    Ann Pharmacother; 2008 Jan; 42(1):32-8. PubMed ID: 18056833
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Domain-specific improvement of cognition on memantine in patients with Alzheimer's disease treated with rivastigmine.
    Riepe MW; Adler G; Ibach B; Weinkauf B; Tracik F; Gunay I
    Dement Geriatr Cogn Disord; 2007; 23(5):301-6. PubMed ID: 17356273
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Treatment of degenerative dementia disorders--who should be treated?].
    Hasselbalch SG; Kampmann JP
    Ugeskr Laeger; 2009 Mar; 171(10):802-5. PubMed ID: 19265606
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Memantine hydrochloride in the treatment of dementia subtypes.
    Peng D; Yuan X; Zhu R
    J Clin Neurosci; 2013 Nov; 20(11):1482-5. PubMed ID: 24035650
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment strategies for the behavioral symptoms of Alzheimer's disease: focus on early pharmacologic intervention.
    Beier MT
    Pharmacotherapy; 2007 Mar; 27(3):399-411. PubMed ID: 17316151
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Role of magnesium ions on the regulation of NMDA receptor--a pharmacopathology of memantine].
    Kato T
    Clin Calcium; 2004 Aug; 14(8):76-80. PubMed ID: 15577101
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Behavioral effects of current Alzheimer's disease treatments: a descriptive review.
    Cummings JL; Mackell J; Kaufer D
    Alzheimers Dement; 2008 Jan; 4(1):49-60. PubMed ID: 18631950
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Memantine therapy of behavioral symptoms in community-dwelling patients with moderate to severe Alzheimer's disease.
    Grossberg GT; Pejović V; Miller ML; Graham SM
    Dement Geriatr Cogn Disord; 2009; 27(2):164-72. PubMed ID: 19194105
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Factors affecting usage patterns of memantine in Alzheimer disease.
    Lerner AJ; McClendon MJ; Sami SA; Ogrocki PK; Adams KB; Smyth KA
    Alzheimer Dis Assoc Disord; 2008; 22(2):137-43. PubMed ID: 18525285
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Reduction of phosphorylated tau during memantine treatment of Alzheimer's disease.
    Degerman Gunnarsson M; Kilander L; Basun H; Lannfelt L
    Dement Geriatr Cogn Disord; 2007; 24(4):247-52. PubMed ID: 17700020
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacology of acetylcholinesterase inhibitors and N-methyl-D-aspartate receptors for combination therapy in the treatment of Alzheimer's disease.
    Geerts H; Grossberg GT
    J Clin Pharmacol; 2006 Jul; 46(7 Suppl 1):8S-16S. PubMed ID: 16809810
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Improvement in behavioural symptoms in patients with moderate to severe Alzheimer's disease by memantine: a pooled data analysis.
    Gauthier S; Loft H; Cummings J
    Int J Geriatr Psychiatry; 2008 May; 23(5):537-45. PubMed ID: 18058838
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Memantine treatment of cognitive symptoms in mild to moderate Alzheimer disease: secondary analyses from a placebo-controlled randomized trial.
    Pomara N; Ott BR; Peskind E; Resnick EM
    Alzheimer Dis Assoc Disord; 2007; 21(1):60-4. PubMed ID: 17334274
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Memantine in moderate-to-severe Alzheimer's disease.
    Bleich S; Wiltfang J; Kornhuber J
    N Engl J Med; 2003 Aug; 349(6):609-10; author reply 609-10. PubMed ID: 12904528
    [No Abstract]   [Full Text] [Related]  

  • 35. Analysis of the effect of memantine in reducing the worsening of clinical symptoms in patients with moderate to severe Alzheimer's disease.
    Wilkinson D; Andersen HF
    Dement Geriatr Cogn Disord; 2007; 24(2):138-45. PubMed ID: 17622761
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The expert consensus guideline series. Treatment of dementia and its behavioral disturbances. Introduction: methods, commentary, and summary.
    Alexopoulos GS; Jeste DV; Chung H; Carpenter D; Ross R; Docherty JP
    Postgrad Med; 2005 Jan; Spec No():6-22. PubMed ID: 17203561
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [The challenge of Alzheimer dementia].
    Pharm Unserer Zeit; 2003; 32(1):77. PubMed ID: 12577765
    [No Abstract]   [Full Text] [Related]  

  • 38. Alzheimer disease and its management: a review.
    Samanta MK; Wilson B; Santhi K; Kumar KP; Suresh B
    Am J Ther; 2006; 13(6):516-26. PubMed ID: 17122533
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Enhancement of long-term spatial memory in adult rats by the noncompetitive NMDA receptor antagonists, memantine and neramexane.
    Zoladz PR; Campbell AM; Park CR; Schaefer D; Danysz W; Diamond DM
    Pharmacol Biochem Behav; 2006 Oct; 85(2):298-306. PubMed ID: 17045636
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cognitive effects of memantine in postmenopausal women at risk of dementia: a pilot study.
    Wroolie TE; Kenna HA; Williams KE; Powers BN; Holcomb M; Lazzeroni L; Rasgon NL
    Acta Neurol Scand; 2009 Mar; 119(3):172-9. PubMed ID: 18705678
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.